CA2065210A1 - Controlled release matrix for pharmaceuticals - Google Patents

Controlled release matrix for pharmaceuticals

Info

Publication number
CA2065210A1
CA2065210A1 CA 2065210 CA2065210A CA2065210A1 CA 2065210 A1 CA2065210 A1 CA 2065210A1 CA 2065210 CA2065210 CA 2065210 CA 2065210 A CA2065210 A CA 2065210A CA 2065210 A1 CA2065210 A1 CA 2065210A1
Authority
CA
Canada
Prior art keywords
controlled release
matrix
pharmaceuticals
release matrix
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2065210
Other languages
French (fr)
Other versions
CA2065210C (en
Inventor
Thinnayam N. Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Thinnayam N. Krishnamurthy
Euroceltique, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US758,883 priority Critical
Priority to US07/758,883 priority patent/US5215758A/en
Application filed by Thinnayam N. Krishnamurthy, Euroceltique, S.A. filed Critical Thinnayam N. Krishnamurthy
Publication of CA2065210A1 publication Critical patent/CA2065210A1/en
Application granted granted Critical
Publication of CA2065210C publication Critical patent/CA2065210C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/15Suppositories
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/964Sustained or differential release type
    • Y10S514/965Discrete particles in supporting matrix
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/966Rectal

Abstract

The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.
CA 2065210 1991-09-11 1992-04-06 Controlled release matrix for pharmaceuticals Expired - Lifetime CA2065210C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US758,883 1991-09-11
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals

Publications (2)

Publication Number Publication Date
CA2065210A1 true CA2065210A1 (en) 1993-03-12
CA2065210C CA2065210C (en) 2000-08-29

Family

ID=25053475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2065210 Expired - Lifetime CA2065210C (en) 1991-09-11 1992-04-06 Controlled release matrix for pharmaceuticals

Country Status (13)

Country Link
US (2) US5215758A (en)
EP (2) EP0698389B1 (en)
JP (2) JP3034125B2 (en)
KR (2) KR100203339B1 (en)
AT (2) AT187887T (en)
AU (1) AU653048B2 (en)
CA (1) CA2065210C (en)
DE (4) DE69215612D1 (en)
DK (2) DK0531611T3 (en)
ES (2) ES2097826T3 (en)
GR (1) GR3022572T3 (en)
IL (2) IL101758A (en)
ZA (1) ZA9203417B (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
EP0652745A1 (en) * 1992-07-31 1995-05-17 Daratech Pty. Ltd. Controlled release implants
US5849240A (en) 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
EP0859603B1 (en) * 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
DK1685839T3 (en) * 1997-12-22 2013-06-24 Euro Celtique Sa Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
EP0978285B1 (en) 1998-08-07 2005-11-23 F. Hoffmann-La Roche Ag Stable pharmaceutical composition of hedgehog proteins and use thereof.
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
KR100463496B1 (en) * 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 Sustained release matrix systems for highly soluble drugs
EE05171B1 (en) 2000-02-08 2009-06-15 Euro-Celtique, S.A. An oral dosage form comprising an opioid agonist in releasable form and a sequestered opioid antagonist, the method for its preparation and its use in medicine
CZ20022707A3 (en) 2000-02-08 2003-01-15 Euroceltique, S. A. Pharmaceutical preparation
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
NZ529231A (en) * 2001-05-02 2009-06-26 Euro Celtique Sa Once-a-day oxycodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
EP1414458B1 (en) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
EP1416842B1 (en) * 2001-07-18 2008-12-31 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
HU0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
AT418967T (en) 2002-04-05 2009-01-15 Euro Celtique Sa Matrix for the modified release of active substances
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc Sustained-release opioid formulations and methods of use
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
JP4808405B2 (en) * 2002-11-26 2011-11-02 シャオジァン ジァン Aqueous sustained-release drug delivery system for highly water-soluble electrolyte drugs
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
AU2004277898B2 (en) 2003-09-25 2009-04-02 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
SI1663229T1 (en) 2003-09-25 2010-08-31 Euro Celtique Sa Pharmaceutical combinations of hydrocodone and naltrexone
TWI483944B (en) 2004-03-30 2015-05-11 Euro Celtique Sa Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc Abuse preventional pharmaceutical formulations
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (en) 2005-09-30 2007-06-19 한국콜마 주식회사 A cosmetic composition of 2 agent and gel patch type for skin lifting, method for manufacturing and using the same
SE530184C2 (en) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesive pharmaceutical film composition containing low viscosity alginates
US20090035354A1 (en) * 2005-12-30 2009-02-05 Mor Research Applications Ltd. Device and Method for Treating the Anal Sphincter
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
PL2034975T3 (en) 2006-06-19 2012-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
EP2049087A2 (en) * 2006-07-21 2009-04-22 LAB International SRL Hydrophilic abuse deterrent delivery system
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (en) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
CA2742227C (en) * 2008-10-31 2017-01-24 Lipid Pharmaceuticals Ehf. The use of fatty acid compositions as laxatives
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
LT2405915T (en) 2009-03-10 2019-03-12 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2445481B1 (en) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
CA2803006A1 (en) 2010-06-30 2012-01-26 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
PT2826467T (en) 2010-12-22 2017-10-25 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
EP2654733B1 (en) 2010-12-23 2016-04-06 Purdue Pharma LP Tamper resistant solid oral dosage forms
TWI643859B (en) 2012-07-16 2018-12-11 羅德科技公司 Process for improved opioid synthesis
NZ715111A (en) 2012-07-16 2016-12-23 Rhodes Technologies Process for improved opioid synthesis
CN102823585B (en) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 Sustained-release preparation for water-soluble pesticide and preparation method of sustained-release preparation
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9127008B2 (en) 2013-03-15 2015-09-08 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
UA116567C2 (en) 2013-07-23 2018-04-10 Євро-Селтік С.А. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
US20170000727A1 (en) * 2013-12-20 2017-01-05 Disphar International B.V. Dry enema product
US9938285B2 (en) 2014-01-15 2018-04-10 Rhodes Technologies Process for improved oxymorphone synthesis
KR101868723B1 (en) 2014-01-15 2018-06-18 로드스 테크놀로지즈 Process for improved oxycodone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (en) * 1987-12-21 1994-10-26 花王株式会社 Multi-layer suppository
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Also Published As

Publication number Publication date
EP0698389A1 (en) 1996-02-28
AT145820T (en) 1996-12-15
ES2097826T3 (en) 1997-04-16
AU653048B2 (en) 1994-09-15
ES2139798T3 (en) 2000-02-16
EP0531611A1 (en) 1993-03-17
EP0531611B1 (en) 1996-12-04
DE69230475D1 (en) 2000-01-27
JP3034125B2 (en) 2000-04-17
IL101758D0 (en) 1992-12-30
JPH05148159A (en) 1993-06-15
US5215758A (en) 1993-06-01
DE69230475T2 (en) 2000-07-13
CA2065210C (en) 2000-08-29
IL101758A (en) 1996-12-05
KR100203339B1 (en) 1999-06-15
JP3624123B2 (en) 2005-03-02
ZA9203417B (en) 1993-01-27
EP0698389B1 (en) 1999-12-22
DE69215612T2 (en) 1997-05-15
DE69215612D1 (en) 1997-01-16
JP2000136149A (en) 2000-05-16
DK0698389T3 (en) 2000-05-01
KR930005616A (en) 1993-04-20
US5508043A (en) 1996-04-16
AU2107392A (en) 1993-03-18
KR100225493B1 (en) 1999-10-15
AT187887T (en) 2000-01-15
GR3022572T3 (en) 1997-05-31
IL117356A (en) 2000-08-31
DK0531611T3 (en) 1997-05-26
IL117356D0 (en) 1996-07-23

Similar Documents

Publication Publication Date Title
TW340045B (en) Extended zero order release pharmaceutical composition
AU589371B2 (en) Purine derivatives and use as therapeutic agent
ES2128369T3 (en) Procedure for the manufacture of solid pharmaceutical forms with prolonged release in two stages.
ES2157944T3 (en) Cores of immediate release pads of insoluble medicines that have a cover of sustained release.
AU641770B2 (en) Dosage form to deliver an antiparkinson agent
DE3854068D1 (en) Adhesive plasters containing pharmaceutically active ingredients.
NL194821B (en) Pharmacologically active catechol derivatives and their compositions.
ES2171471T3 (en) System for oral administration of desferrioxamine.
KR900700099A (en) Topical administration metronidazole formulations and their therapeutic use
MY115662A (en) Novel compounds with analgesic effect
CA2145093A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
BR9206077A (en) Composition, use of the same, process to prepare a surgical implant to inhibit fibrosis, improved implant, process to inhibit fibrosis, granulation and scarring.
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
CA2131647A1 (en) Sustained Release Heterodisperse Hydrogel Systems for Insoluble Drugs
AU2467788A (en) Device for administering an active agent to the skin or mucosa
HUT50050A (en) Pharmaceutical compositions with controlled release of active ingredient and process for producing such compositions
MD1233C2 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
PE14595A1 (en) Parathyroid hormone and raloxifene for increasing bone mass
ES2159591T3 (en) Composition of controlled release.
HUT52075A (en) Process for producing pharmaceutical compositions comprising (aminomethyloxooxazolidinyl)-ethylene benzene derivatives as active ingredient and for producing the active ingredient
IE863420L (en) Xanthan gum sustained drug release composition
NZ537410A (en) Extended release formulations of clarithromycin that minimise adverse effects and provide at least equivalent to tablet or liquid formulations
JPH04234811A (en) Sustained release of active agent from bioadhesive microcapsule
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
HUT55951A (en) Fungicidal compositions comprising acrylic acid derivatives as active ingredient and process for producing the active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry